The Russian Ministry of Health has registered the antiviral drug Remdesivir PSK
The Russian full-cycle biopharmaceutical company PSK Pharma has registered the antiviral drug Remdesivir PSK.
According to UN data, for three years of the COVID-19 pandemic, in WHO has received almost SEVEN million reports of deaths from coronavirus infection. The virus still continues to mutate and may subsequently cause new outbreaks of morbidity and mortality.
Remdesivir PSC stops the multiplication of the virus, which helps the body overcome the infection and the person recover faster, and reduces the incidence of deaths.
Remdesivir is included in the guidelines for the prevention, diagnosis and treatment of coronavirus infection (COVID-19) (Version 18 dated October 26, 2023) and is indicated for use in adults and children aged from sp;12 years (with a body weight of at least 40 kg) with:
- pneumonia requiring additional oxygen therapy
- increased risk of progression to severe COVID-19 that does not require supplemental oxygen therapy.
The company is developing a wide range of vital and essential medicines (VED) for use in hospital segment.